Agnė Pociūtė

Agnė Pociūtė

Auto-generated profile, based on publicly available information

Agnė Pociūtė

Department of Stem Cell Biology State Research Institute Centre for Innovative Medicine Vilnius Lithuania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
KKKarolina Kriaučiūnaitė
Karolina Kriaučiūnaitė
APAgnė Pociūtė
Agnė Pociūtė
AKAida Kaušylė
Aida Kaušylė
JPJustina Pajarskienė
Justina Pajarskienė
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky
APAugustas Pivoriunas
Augustas Pivoriunas

25 September 2025 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
JPJustina Pajarskienė
Justina Pajarskienė
AVAgnė Vailionytė
Agnė Vailionytė
IUIeva Uogintė
Ieva Uogintė
Steigvilė ByčenkienėSteigvilė Byčenkienė
Steigvilė Byčenkienė
APAgnė Pociūtė
Agnė Pociūtė
RARuta Aldonyte
Ruta Aldonyte

27 April 2026 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
APAgnė Pociūtė
Agnė Pociūtė
VTVirginijus Tunaitis
Virginijus Tunaitis
AŽArūnas Žebrauskas
Arūnas Žebrauskas
VPVladimirs Pilipenko
Vladimirs Pilipenko
BJBaiba Jansone
Baiba Jansone
APAugustas Pivoriunas
Augustas Pivoriunas
Background: Therapeutic applications require large amounts of extracellular vesicles (EVs) that cannot be obtained by standard laboratory protocols. Since culturing parameters and isolation methods can significantly affect the molecular composition and therapeutic efficacy of EVs, the development of a new scale-up protocol should be followed by the molecular fingerprinting and validation of therapeutic potential in vivo. Methods: We developed a new scale-up protocol based on microcarrier culture (3D) of immortalized human dental pulp stem cells in a spinning bioreactor and subsequent isolation of EVs by 2-step tangential flow filtration (TFF) and size exclusion chromatography (SEC). Results: A new scale-up protocol increased EV yields by 463-fold. When compared with ultracentrifugation (UC), isolation using TFF/SEC substantially reduced the complexity of proteomic cargo, whereas culture conditions (2D vs. 3D) affected miRNA, but not mRNA and proteomic content of the EVs. We next compared the therapeutic efficacy of both EV products in 6-hydroxydopamine rat model of Parkinson’s disease (PD). The same amounts of EVs derived from standard 2D cultures by UC and a new large-scale protocol were intranasally administered to PD rats, where they similarly improved gait and cognitive functions, preserved nigrostriatal tyrosine hydroxylase density and suppressed neuroinflammation. Notably, both EV preparations were enriched in proteins and miRNAs associated with anti-oxidative and anti-inflammatory responses. Conclusion: Our protocol allows large-scale production of EVs that are therapeutically effective in the pre–clinical model of PD.

8 March 2026 in The FASEB Journal
Verified
Journal Article
Closed access
APAgnė Pociūtė
Agnė Pociūtė
KMKotryna Milovanovaitė
Kotryna Milovanovaitė
AJAgnė Jokubauskytė
Agnė Jokubauskytė
APAugustas Pivoriūnas
Augustas Pivoriūnas

29 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
APAgnė Pociūtė
Agnė Pociūtė
KKKarolina Kriaučiūnaitė
Karolina Kriaučiūnaitė
AKAida Kaušylė
Aida Kaušylė
BZBirutė Zablockienė
Birutė Zablockienė
TATadas Alčauskas
Tadas Alčauskas
APAugustas Pivoriunas
Augustas Pivoriunas
The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) instigated the most serious global health crisis. Clinical presentation of COVID-19 frequently includes severe neurological and neuropsychiatric symptoms. However, it is presently unknown whether and to which extent pathological impairment of blood-brain barrier (BBB) contributes to the development of neuropathology during COVID-19 progression. In the present study we used human induced pluripotent stem cells-derived brain endothelial cells (iBECs) to study the effects of blood plasma derived from COVID-19 patients on the BBB integrity in vitro . We also performed a comprehensive analysis of the cytokine and chemokine profiles in the plasma of COVID-19 patients, healthy and recovered individuals. We found significantly increased levels of interferon γ-induced protein 10 kDa (IP-10), hepatocyte growth factor (HGF), and interleukin-18 (IL-18) in the plasma of COVID-19 patients. However, blood plasma from COVID-19 patients did not affect transendothelial electrical resistance (TEER) in iBEC monolayers. Our results demonstrate that COVID-19-associated blood plasma inflammatory factors do not impair BBB integrity directly and suggest that pathological remodelling of BBB during COVID-19 may occur through indirect mechanisms.